Abstract
India has emerged as a strong base for clinical trials in recent times. Due to
the multitude of benefits it offers, the country is fast growing as a centre
for conducting clinical trials for many international companies. So RNCOS has
launched its research report called "Booming Clinical Trials Market in India"
to give first-hand information on the Indian clinical trials market. It
investigates the key competitive advantages/disadvantages India has when it
comes to conducting clinical trials in the country. The report also does a
through study of the key factors which evaluate the country' s clinical trials,
such as patient pool, patient recruitment, cost, time, government regulations,
intellectual property, human resources, infrastructure and ethical issues.
India, with its huge patient base, low cost advantage, completion of clinical
trials on time, improving infrastructure, and with a strong government support
is witnessing a double digit growth in its clinical trials market. All major
pharmaceutical companies and Clinical Research Organizations (CROs) have
already started conducting their clinical trials in India, and with improving
infrastructure, industry friendly regulations and trained workforce, the
growth is only likely to increase in future.
However, to achieve its goal of becoming a global hub of clinical trials, the
country will have to overcome challenges like unethical trials, delay in trial
approval, inappropriate protection of clinical data, and lack of Good Clinical
Practice (GCP) certified sites and investigators.
Key Findings
- Indian clinical trials market is expected to grow at a CAGR of nearly 36%
between 2006 and 2011 to register revenues worth US$ 546 Million in future.
- One of the biggest advantages of conducting clinical trials in India is
the availability of a large patient pool that can be recruited at much shorter
time then it takes to recruit patients in the west.
- India by 2011 will be conducting more than 15% of the total global
clinical trials.
- India presently lacks in GCP trained investigators (which are less than
1000). Their demand is projected to reach between 3000 and 6000 by 2010.
- India does not provide "Data Exclusivity" in clinical trials unlike the US
and EU members.
- The salaries of a clinical data specialist and Medical writer in India are
around 15% and 9% respectively of what they get in the US.
- The clinical trials market will drive the growth of the Diagnostics and
Pathology Industry in India.
Key Issues and Facts Analyzed
- Evaluation of past, current and future market trends.
- Discussion about the factors driving the clinical research market.
- An analysis of the opportunities created by the market.
- A review on the government regulations on the market.
- An analysis of the major challenges faced by the market.
Key Players Analyzed
This section provides the overview, key facts financial information of
prominent players in the Indian clinical trials market like Quintiles,
Ranbaxy, Dr Reddy' s Laboratories, Roche, Pfizer etc.
Research Methodology Used
Information Sources
Information has been sourced from books, newspapers, trade journals, and white
papers, industry portals, government agencies, trade associations, monitoring
industry news and developments, and through access to more than 3000 paid
databases.
Analysis Methods
The analysis methods include ratio analysis, historical trend analysis, linear
regression analysis using software tools, judgmental forecasting, and cause
and effect analysis.
View Cart
